ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 722

Systemic Sclerosis Associated Pulmonary Hypertension – Is Pulmonary Veno-Occlusive Disease As Common As They Say?

Benjamin E. Schreiber1, Greg Keir2, D. Dobarro3, Clive Handler4, Svetlana Nihtyanova5, Jay Suntharaligam6, Nicola Sverzelatti7, Graham Robinson6, David Hansell8, Athol U. Wells9, Christopher P. Denton10 and John G. Coghlan11, 1Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 2Royal Brompton Hospital, United Kingdom, 3Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom, 4Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, 5Department of Rheumatology, Royal Free Hospital, Medical School, London, England, 6Royal United Hospital, Bath, United Kingdom, 7University of Parma, Parma, Italy, 8Royal Brompton Hospital, London, United Kingdom, 9Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, 10Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 11National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Computed tomography (CT), Pulmonary complications and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recent reviews have suggested a high prevalence of pulmonary veno-occlusive disease (PVOD) amongst patients with systemic sclerosis (SSc) associated pulmonary hypertension (PH). Interlobular septal thickening (IST) and centrilobular nodules (CLN) are reported to correlate with presence of PVOD, which is associated with worse outcomes in small series. We tested this hypothesis on a large series of systemic sclerosis patients who underwent evaluation for pulmonary hypertension.

Methods:

A retrospective study of patients with systemic sclerosis who underwent CT of the chest within six months of a diagnostic right heart catheterisation. The CTs were blindly scored by two independent radiologists including detailed assessment for extent of interstitial lung disease (using the Goh et al. AJRCCM 2008 staging system), IST and CLN. Each lung quadrant was scored separately for interlobular septal thickening (IST) with score 0-5 and centrilobular nodules (CLN), score 0-3. Survival data were collected on all patients.

Results:

Mean age was 57.8 (range 22-85). 78% were female. 84 patients had LcSSc, 32 had DcSSc and 1 had MCTD. CT scans were performed a mean of 2.7 months from the RHC.

There was limited or no ILD extent (<20%) in 46 patients (43%), ~20% in 28% and extensive (>20%) in 30%. On right heart catheterisation 53% had precapillary PH while 47% did not.

95 scans were reported independently in a blinded fashion by two radiologists. Of the remaining 95 patients, 49 had PAH and 46 did not. Of those with PH, 18 had <20% ILD, 18 had ~20% ILD and 13 had >20% ILD. Amongst patients with PH, there was a weak trend towards worse survival in patients with more lung disease (HR 1.5, 95% CI 0.89,2.52, p=0.13).

IST of any degree was observed in 15% of patients and CLN in 18%. Mean IST score was 1 (on a scale of 0-4) and mean CLN score was 0.63 (scale of 0-2). IST was not associated with extent of ILD (p=0.19 by chi-square), and nor was CLN (p=0.74, by chi-square). IST did not correlate with PVR (R2=2%) whereas CLN did correlate with PVR (R2=15.7%).

By Cox proportional hazards analysis, PVR was a strong predictor of death (p=0.001). Increasing IST was associated with worse survival on univariate analysis (p=0.038) however statistical significance is lost (p=0.11) after adjustment for age.

Increasing CLN is strongly associated with higher mortality (p=0.013) even after adjustment for age, gender, extent of interstitial lung disease and mean pulmonary artery pressure (p=0.047). This is particularly observed in patients without PH (p=0.004 on this multivariate analysis) rather than in patients with PH (where p=0.19 on multivariate analysis). However, CLN is not a significant predictor after adjustment for PVR (p=0.18). 

Conclusion:

Interlobular septal thickening and centrilobular nodules are frequently seen in patients with systemic sclerosis and are each associated with worse survival. However, IST increases with age and CLN increases with worsening pulmonary vascular resistance. In our study they were not independent predictors of worse outcome in systemic sclerosis. It is therefore possible that the significance of these radiological findings is primarily as markers of known prognostic risk factors.


Disclosure:

B. E. Schreiber,

Actelion Pharmaceuticals US,

8, 9,

GSK,

5;

G. Keir,
None;

D. Dobarro,

Eli Lilly and Company,

9;

C. Handler,

Actelion Pharmaceuticals US,

9,

Pfizer Inc,

9;

S. Nihtyanova,
None;

J. Suntharaligam,

GSK,

8,

Actelion Pharmaceuticals US,

8,

Novartis Pharmaceutical Corporation,

8;

N. Sverzelatti,
None;

G. Robinson,
None;

D. Hansell,

Astra Zeneca ,

5,

Boehringer Ingelheim,

5;

A. U. Wells,
None;

C. P. Denton,

Actelion Pharmaceuticals US,

5,

GlaxoSmithKline,

5,

Pfizer Inc,

5,

United Therapeutics,

5;

J. G. Coghlan,

GSK,

9,

Bayer,

9,

Pfizer Inc,

9,

Eli Lilly and Company,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-sclerosis-associated-pulmonary-hypertension-is-pulmonary-veno-occlusive-disease-as-common-as-they-say/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology